FSHR rs7747753: Understanding Your Genetic Variant
The rs7747753 variant is a genetic polymorphism located within the promoter region of the FSHR gene. It is studied for its potential role in modulating how the body's follicle-stimulating hormone receptor functions, which may influence ovarian response during fertility treatments.
What each genotype means
Typical FSH receptor expression
You carry two copies of the G allele (historically referred to as -29G in promoter studies). Research suggests this baseline genotype maintains typical FSH receptor promoter activity and standard ovarian responsiveness during assisted reproductive therapies like IVF. However, because overall evidence linking promoter variations to ovarian stimulation outcomes remains limited and mixed across studies, you should always discuss any fertility medication protocols or gonadotropin dosing directly with your reproductive endocrinologist.
Carried by approximately 27% to 36% of individuals across global populations, being most common in East Asian ancestries.
Intermediate promoter activity
You carry one copy of the A allele and one copy of the G allele. In vitro and clinical observational studies suggest this heterozygous genotype is associated with intermediate FSH receptor expression and average gonadotropin sensitivity during controlled ovarian stimulation. Because clinical evidence is limited and non-genetic factors play a substantial role in ovarian response, any individualized medication planning should be determined in consultation with your clinician or pharmacist.
Carried by approximately 48% to 50% of individuals worldwide, representing the most common genotype across most ancestral cohorts.
Altered FSH receptor response
You carry two copies of the A allele (frequently noted in reproductive literature as -29A or -29A/A). Some studies indicate this genotype is correlated with reduced promoter transcriptional activity, which may relate to lower sensitivity to follicle-stimulating hormone and higher requirement for exogenous gonadotropins during IVF protocols. Because evidence remains limited and conflicting between study cohorts, never adjust any prescribed fertility medications independently and review all dosing decisions with your healthcare provider.
Carried by approximately 16% to 23% of individuals globally, observed slightly more frequently in European and African populations.
What is rs7747753?
The rs7747753 variant is a single nucleotide polymorphism (SNP) situated in the promoter region of the FSHR gene. While many studies on the FSHR gene focus on coding variants that change amino acids, such as those at codons 307 and 680, rs7747753 is located in the regulatory sequence. The promoter region is critical because it acts as a control switch, determining how much of the FSHR protein is produced by the cell. By sitting in this regulatory area, rs7747753 is hypothesized to influence the expression levels of the receptor rather than the structure of the protein itself. Because it is a non-coding variant, its functional impact is often more subtle and harder to measure than variants that directly alter the protein's shape or binding affinity.
The Role of the FSHR Gene
The FSHR gene provides instructions for making the follicle-stimulating hormone receptor. This receptor is found primarily on the surface of cells in the ovaries and testes. In the ovaries, the receptor is essential for the development of ovarian follicles, which contain the eggs. When follicle-stimulating hormone (FSH) binds to this receptor, it triggers a signaling cascade that promotes follicle growth and maturation. Because this pathway is central to reproduction, variations in the gene can theoretically alter how an individual responds to natural hormone levels or to exogenous hormones administered during fertility treatments like in vitro fertilization (IVF). Understanding these variations is a subject of ongoing research into why individuals exhibit different sensitivities to hormonal stimulation.
Research and Evidence Strength
Research into rs7747753 is currently considered to have limited evidence regarding its clinical impact. While some studies have investigated whether promoter variants in FSHR correlate with ovarian response or the amount of medication required during IVF, the findings are often mixed or show only small effect sizes. It is important to note that genetic associations with complex traits like fertility are rarely determined by a single SNP. Instead, they are likely the result of a combination of multiple genetic factors, environmental influences, and lifestyle variables. Because the evidence is not definitive, this variant is not currently used as a standard diagnostic tool in clinical practice. Further large-scale, multi-ethnic studies are required to clarify whether this specific promoter variant has a consistent, measurable effect on reproductive outcomes.
Population Frequency
The rs7747753 variant is relatively common, with a minor allele frequency typically reported between 0.40 and 0.48 across diverse worldwide populations. This high frequency suggests that the variant is a standard part of human genetic diversity rather than a rare mutation.
What This Information Means for You
If you have received information about your rs7747753 genotype, it is important to view it within the context of current scientific uncertainty. Because the evidence linking this specific SNP to clinical outcomes is limited, it cannot be used to predict your personal fertility or your specific response to medical treatments. Genetic markers are only one piece of a much larger biological puzzle. If you are undergoing fertility treatments or have concerns about reproductive health, you should always discuss your medical history, hormone levels, and treatment options with a qualified reproductive endocrinologist or fertility specialist. They can provide guidance based on your clinical profile rather than relying on individual genetic variants, which are not currently validated for routine clinical decision-making.
How common is this variant?
The rs7747753 variant is common, with a minor allele frequency ranging from approximately 0.40 to 0.48 across various global populations.
Frequently asked questions
Can rs7747753 predict my IVF success?
No. Current research indicates that the evidence linking this variant to IVF outcomes is limited and inconsistent. It is not a reliable predictor of fertility success.
Should I change my medication based on this SNP?
Absolutely not. You should never alter your medication or treatment plan based on a single genetic variant. Always consult your fertility specialist regarding your treatment protocol.
Is rs7747753 a disease-causing mutation?
No, it is classified as a polymorphism, which is a common variation in the DNA sequence. It is not considered a disease-causing mutation.
Where can I find more information on FSHR variants?
You can search databases like PubMed or the GWAS Catalog for peer-reviewed research. For clinical context, speak with a genetic counselor or your healthcare provider.
Sources & further reading
Educational information only, last refreshed 10/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7747753?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FSHR
This variant is linked to ovarian dysgenesis, potentially affecting hormonal regulation and physical appearance related to sexual maturation.
This variant is associated with ovarian dysgenesis, which can impact secondary sexual characteristics and physical development.
Common missense variant (Thr307Ala) in the follicle-stimulating hormone receptor gene, associated with variations in ovarian response to gonadotropin stimulation.
Variant in the follicle stimulating hormone receptor gene associated with altered ovarian response.
FSHR intronic variant associated with ovarian response to follicle-stimulating hormone stimulation in assisted reproductive technology.
Common non-coding regulatory variant in the follicle stimulating hormone receptor locus influencing ovarian sensitivity and gonadotropin dosage requirements.